Predicting Phenotype and Emerging Strains among Chlamydia trachomatis Infections
Deborah Dean , William J. Bruno, Raymond Wan, João P. Gomes, Stéphanie Devignot, Tigist Mehari, Henry J.C. de Vries, Servaas A. Morré, Garry Myers, Timothy D. Read, and Brian G. Spratt
Author affiliations: Children’s Hospital Oakland Research Institute, Oakland, California, USA (D. Dean, R. Wan, T. Mehari); University of California, San Francisco, California, USA (D. Dean); University of California, Berkeley, California, USA (D. Dean); Los Alamos National Laboratories, Los Alamos, New Mexico, USA (W.J. Bruno); National Institute of Health, Lisbon, Portugal (J.P. Gomes); Institut de Médecine Tropicale du Service de Santé des Armées, Marseille, France (S. Devignot); University of Amsterdam, the Netherlands (H.J.C. de Vries); Vrije Universiteit Medical Center, Amsterdam (S.A. Morré); University of Maryland School of Medicine, Baltimore, Maryland, USA (G. Myers); Emory University, Atlanta, Georgia, USA (T.D. Read); Imperial College, London, UK (B.G. Spratt)
Figure 5. SplitsTree obtained by using concatenated sequences of the 7 loci for the 87 isolates. Cluster I, noninvasive, nonprevalent Chlamydia trachomatis strains (gold) with trachoma Subcluster I (red); cluster II, invasive lymphogranuloma venereum (LGV) isolates (purple); and cluster III, noninvasive globally prevalent sexually transmitted infection (STI) strains (blue). Isolates colored green represent putative recombinant strains. Scale bar indicates number of substitutions per site.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.